Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBIT Margin: 2017-2025

Historic EBIT Margin for Crinetics Pharmaceuticals (CRNX) over the last 6 years, with Sep 2025 value amounting to -99,710.49%.

  • Crinetics Pharmaceuticals' EBIT Margin was N/A to -99,710.49% in Q3 2025 from the same period last year, while for Sep 2025 it was -24,707.76%, marking a year-over-year change of. This contributed to the annual value of -32,613.47% for FY2024, which is 2706630.00% down from last year.
  • Crinetics Pharmaceuticals' EBIT Margin amounted to -99,710.49% in Q3 2025, which was down 696.22% from -12,522.99% recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year EBIT Margin high stood at -1,080.39% for Q1 2022, and its period low was -99,710.49% during Q3 2025.
  • For the 3-year period, Crinetics Pharmaceuticals' EBIT Margin averaged around -24,941.28%, with its median value being -14,784.18% (2023).
  • Data for Crinetics Pharmaceuticals' EBIT Margin shows a peak YoY increase of 822,463bps (in 2025) and a maximum YoY decrease of 1,937,120bps (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Crinetics Pharmaceuticals' EBIT Margin stood at -6,707.48% in 2022, then slumped by 755,760bps to -17,045.38% in 2023, then plummeted by 1,538,375bps to -20,747.62% in 2024, then skyrocketed by 822,463bps to -99,710.49% in 2025.
  • Its EBIT Margin was -99,710.49% in Q3 2025, compared to -12,522.99% in Q2 2025 and -30,860.11% in Q1 2025.